Journey Strategic Wealth’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$6.87M Buy
7,471
+1,068
+17% +$1.08M 0.17% 38
2025
Q4
$6.88M Buy
6,403
+908
+17% +$868K 0.18% 40
2025
Q3
$4.19M Sell
5,495
-467
-8% -$348K 0.12% 58
2025
Q2
$4.65M Buy
5,962
+2,484
+71% +$1.93M 0.15% 49
2025
Q1
$2.87M Buy
3,478
+468
+16% +$389K 0.1% 63
2024
Q4
$2.32M Buy
3,010
+92
+3% +$76.2K 0.09% 64
2024
Q3
$2.59M Buy
2,918
+490
+20% +$441K 0.09% 57
2024
Q2
$2.2M Buy
2,428
+171
+8% +$137K 0.09% 44
2024
Q1
$1.76M Buy
2,257
+688
+44% +$490K 0.08% 47
2023
Q4
$915K Sell
1,569
-42
-3% -$24.5K 0.04% 69
2023
Q3
$865K Sell
1,611
-187
-10% -$96.4K 0.04% 66
2023
Q2
$843K Sell
1,798
-147
-8% -$61.6K 0.04% 64
2023
Q1
$668K Sell
1,945
-54
-3% -$18.2K 0.07% 83
2022
Q4
$731K Sell
1,999
-53
-3% -$18.8K 0.09% 73
2022
Q3
$664K Buy
2,052
+379
+23% +$120K 0.09% 53
2022
Q2
$543K Hold
1,673
0.07% 54
2022
Q1
$479K Buy
1,673
+37
+2% +$9.52K 0.05% 54
2021
Q4
$452K Buy
+1,636
New +$415K 0.05% 82

Other funds holding LLY

Journey Strategic Wealth's LLY Position: Q1 2026 in Review

Journey Strategic Wealth increased its Eli Lilly (LLY) stake by 17% in Q1 2026, buying an estimated $1.08M and bringing the position to 7,471 shares worth $6.87M. The position accounts for 0.17% of the portfolio, ranked #38.

Journey Strategic Wealth first reported a position in LLY in Q4 2021 and has held it in 18 quarters since. The position peaked at $6.88M in Q4 2025. 4,353 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

  • Journey Strategic Wealth held 7,471 shares of Eli Lilly worth $6.87M as of Q1 2026.
  • Journey Strategic Wealth bought 1,068 Eli Lilly shares in Q1 2026, an estimated $1.08M.
  • Eli Lilly made up 0.17% of Journey Strategic Wealth's portfolio in Q1 2026, its #38 holding.
  • Journey Strategic Wealth first reported a position in Eli Lilly in Q4 2021 and has held it in 18 quarters since.
  • Journey Strategic Wealth's Eli Lilly position peaked at $6.88M in Q4 2025.
  • 4,353 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on Journey Strategic Wealth's 13F filing for Q1 2026, filed 15 Apr 2026.